Lantern Pharma Gets Orphan Status LP-184

FDA has granted Lantern Pharma an orphan drug designation for LP-184 and its use in treating glioblastoma multiforme (GBM) and other malignant gliomas. LP-184 is a small molecule drug candidate and next generation alkylating agent that “preferentially damages DNA in cancer cells that over-express certain biomarkers or that harbor mutations in DNA repair pathways,” the company says.

“We recently reported positive preclinical data that demonstrated LP-184 inhibits tumor growth by greater than 106% and improved survival in animal models of GBM,” the company says. “We believe LP-184’s ability to cross the blood-brain barrier, together with its anti-tumor efficacy and sensitivity correlations with relevant biomarkers, highlight LP-184’s potential to be used as both monotherapy as well as a synergistic agent in combination with other drugs to address the unmet needs in GBM and other aggressive central nervous system tumors.”